CHF364.00
4.21% yesterday
SIX Swiss Exchange, Nov 15, 05:31 pm CET
ISIN
CH0019396990
Symbol
YPSN
Sector

Ypsomed Stock price

CHF364.00
-34.50 8.66% 1M
+33.00 9.97% 6M
+61.00 20.13% YTD
+94.00 34.81% 1Y
+179.60 97.40% 3Y
+231.60 174.92% 5Y
+278.50 325.73% 10Y
SIX Swiss Exchange, Closing price Fri, Nov 15 2024
-16.00 4.21%
ISIN
CH0019396990
Symbol
YPSN
Sector

Key metrics

Market capitalization CHF5.18b
Enterprise Value CHF5.45b
P/E (TTM) P/E ratio 69.68
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 8.84
P/S ratio (TTM) P/S ratio 8.39
P/B ratio (TTM) P/B ratio 8.33
Dividend yield 0.53%
Last dividend (FY24) CHF2.00
Revenue growth (TTM) Revenue growth 21.33%
Revenue (TTM) Revenue CHF617.07m
EBIT (operating result TTM) EBIT CHF102.59m
Free Cash Flow (TTM) Free Cash Flow CHF-8.12m
EPS (TTM) EPS CHF5.45
P/E forward 43.90
P/S forward 7.79
EV/Sales forward 8.20
Show more

Is Ypsomed a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Ypsomed Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Ypsomed forecast:

3x Buy
43%
3x Hold
43%
1x Sell
14%

Analyst Opinions

7 Analysts have issued a Ypsomed forecast:

Buy
43%
Hold
43%
Sell
14%

Financial data from Ypsomed

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Sep '24
+/-
%
617 617
21% 21%
100%
- Direct Costs 398 398
15% 15%
65%
219 219
34% 34%
35%
- Selling and Administrative Expenses 40 40
41% 41%
6%
- Research and Development Expense - -
-
-
179 179
33% 33%
29%
- Depreciation and Amortization 76 76
1% 1%
12%
EBIT (Operating Income) EBIT 103 103
78% 78%
17%
Net Profit 74 74
3% 3%
12%

In millions CHF.

Don't miss a Thing! We will send you all news about Ypsomed directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Ypsomed Holding AG engages in the development and manufacture of injection systems for self-medication of drugs by patients, most notably used to treat diabetes. Its products include DiaExpert, BGMS, OmniPod, YpsoPump & Orbit, Pen needles, Injection systems, and Contract manufacturing. The company operates through the following business segments: Ypsomed Diabetes Care, and Ypsomed Delivery Systems. The Ypsomed Diabetes Care segment owns, manufactures and trade products are marketed under the brand mylife Diabetes care directly to hospitals, physicians, pharmacies and patients via Ypsomed's subsidiaries and distributors. The Ypsomed Delivery Systems segment concerns B2B business and is directly managed by the company. Ypsomed Holding was founded by Wilhelm Michel on December 29, 2003 and is headquartered in Burgdorf, Switzerland.

Head office Switzerland
CEO Simon Michel
Employees 2,296
Founded 2003
Website www.ypsomed.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today